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Abstract Microvascular injury is present in a large pro-
portion of patients with ST-elevation myocardial infarc-
tion (STEMI) despite successful revascularization.
Ticagrelor potentially mitigates this process by exerting
additional adenosine-mediated effects. This study aims
to determine whether ticagrelor is associated with a bet-
ter microvascular function compared to prasugrel as
maintenance therapy after STEMI. A total of 110 pa-
tients presenting with STEMI and additional intermedi-
ate stenosis in another coronary artery will be studied
after successful percutaneous coronary intervention
(PCI) of the infarct-related artery. Patients will be ran-
domized to treatment with ticagrelor or prasugrel for
1 year. FFR-guided PCI of the non-infarct-related artery
will be performed at 1 month. Microvascular function
will be assessed by measurement of the index of
microcirculatory resistance (IMR) in the infarct-related
artery and non-infarct-related artery, immediately after
primary PCI and after 1 month. The REDUCE-MVI
study will establish whether ticagrelor as a maintenance
therapy may improve microvascular function in patients
after revascularized STEMI.
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Abbreviations
AE Adverse event
CMR Cardiovascular magnetic resonance
DES Drug-eluting stent
FFR Fractional flow reserve
IMR Index of microcirculatory resistance
MRI Magnetic resonance imaging
MVI Microvascular injury
OCT Optical coherence tomography
PCI Percutaneous coronary intervention
RCA Right coronary artery
RHI Reactive hyperemia index
SAE Serious adverse event
STEMI ST-elevation myocardial infarction
Introduction
Percutaneous coronary intervention (PCI) in patients with ST-
elevation myocardial infarction (STEMI) leads to an im-
proved patency rate of the infarct-related artery, a lower inci-
dence of heart failure, and ultimately an improved survival as
compared to thrombolytic treatment [1]. However, problems
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that frequently occur after restoration of the epicardial blood
flow are inadequate myocardial reperfusion and microvascu-
lar injury (MVI) [2].
MVI can be visualized by non-invasive methods using
cardiovascular magnetic resonance imaging (CMR) or
measured by invasive methods such as intracoronary
thermodilution [3]. MVI as assessed by CMR is related
to left ventricular remodeling and clinical outcome after
STEMI [4, 5].
From the acute to late phase of a revascularized myo-
cardial infarction, several mediators are thought to con-
tribute to the development of MVI. These factors in-
volve the appearance of intraluminal platelets, fibrin
thrombi, and neutrophilic granulocytes, resulting in in-
flammatory cell plugging, formation of microthrombi,
endothelial activation and injury, and finally MVI.
Vasoconstriction follows as a result of endothelial dys-
function with decreased levels of nitric oxide and in-
creased levels of endothelin-1. Furthermore, the imbal-
ance in coagulation factors and influx of inflammatory
cells can cause vascular leakage and hemorrhage [6, 7].
Adenosine, a substance naturally present in the blood,
has an inhibitory effect on several of these processes
[8, 9].
Currently, in patients with STEMI, the P2Y12-recep-
tor antagonists ticagrelor and prasugrel, in addition to
aspirin, are the recommended antiplatelet drugs accord-
ing to European and American guidelines [10, 11]. The
efficacy of ticagrelor and prasugrel in reducing platelet
activity is comparable [12]. The long-term effects on clinical
outcome are presently subject to investigation [13].
Interestingly, ticagrelor, besides its antiplatelet effects, in-
creases adenosine concentration in the blood plasma by inhi-
bition of intracellular reuptake and might therefore have an
additional beneficial effect by preventing MVI [14–17].
Therefore, we designed a randomized study, comparing the
effects of ticagrelor and prasugrel on MVI and endothelial
dysfunction after STEMI.
Methods
The Reducing Micro Vascular dysfunction In revascularized
ST-elevation myocardial infarction patients by off-target prop-
erties of ticagrelor (REDUCE-MVI) study is a multicenter
trial with a prospective, randomized, open-label, blinded-
endpoint (PROBE) study design. Current participating centers
are the VU University Medical Center (Amsterdam, the
Netherlands), the Erasmus Medical Center (Rotterdam, the
Netherlands), the Medisch Spectrum Twente (Enschede, the
Netherlands), and the Hospital Clínico San Carlos (Madrid,
Spain). A flow chart of the study design is shown in Fig. 1.
Patient Enrolment
On hospital arrival, patients presenting with an acute
STEMI will be screened for participation in the study
according to the inclusion and exclusion criteria
(Table 1). ST-elevation criteria are used according to
current ESC guidelines [10]. After successful PCI,
witnessed oral informed consent will be obtained and
documented, before proceeding with study measure-
ments. After the procedure, written informed consent
in native language will be obtained from all individual
participants that will be included in the study. Hereafter,
patients will be randomized to treatment with either
ticagrelor or prasugrel. A total of 110 patients will be
enrolled in the study.
Coronary Angiography and Revascularization
at Index and 1 Month
PCI will be performed according to standard procedures
and is left to the discretion of the operator. All patients
will receive a loading dose of heparin, aspirin, and the
P2Y12 inhibitor ticagrelor in the ambulance before pri-
mary PCI with a third-generation drug-eluting stent
(DES) (standard of care in participating centers). After
successful primary PCI, myocardial tissue perfusion of
the infarct-related area will be assessed by determining
the myocardial blush grade [18].
After 1 month, patients will undergo clinically indicated
FFR-guided PCI of the intermediate lesion in the non-
infarct-related artery.
Pharmacologic Treatment
Patients will be randomly assigned to use either ticagrelor
90 mg BID or prasugrel 10 mg SID as a maintenance therapy
continued for 1 year according to current international guide-
lines [19]. Concomitant medical therapy will be left to the
discretion of the treating physician.
Endpoints
The primary objective of this study is to determine wheth-
er ticagrelor at treatment steady-state in revascularized
STEMI patients is associated with an improved microvas-
cular function as measured with IMR, compared to
prasugrel. Both treatment groups are subjected to the same
measurements at three time points. The function of the
coronary microcirculation is considered as primary end-
point which will be assessed by determining the index
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of the microcirculatory resistance (IMR) [3]. Microcirculatory
resistance measurements of the infarct-related artery and sec-
ondarily of the non-infarct-related artery will be performed
directly after primary PCI and after 1 month. Secondary end-
points will be coronary endothelialization, left ventricular
function, and infarct size at 1 month, as well as peripheral
endothelial function and several biochemical markers of en-
dothelial function, measured at baseline and at follow-up after
1 month and 1 year.
Index of Microcirculatory Resistance
IMR in the infarct-related artery will be measured after
1 month and compared to IMR immediately after primary
PCI. Secondly, IMR in the non-infarct-related artery will be
determined after 1 month and compared to measurements at
baseline (Fig. 2).
By using a coronary pressure and temperature-sensitive
guidewire (Certus™, ST Jude Medical, Uppsala, Sweden)
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Acute STEMI <12 h
The patient has received a loading dose ticagrelor 180 mg before start of PCI
Successful PCI of the infarct-related artery with a modern DES
Intermediate stenosis in a non-infarct-related artery (50–90 %)
Provision of informed consent
Age <18 or ≥75
Body weight <60 kg
History of myocardial infarction, coronary artery bypass graft,
stroke, or transient ischemic attack
Congestive heart failure, left ventricle ejection fraction <35 %
Severe liver or kidney dysfunction
Bleeding diathesis, platelet count <100,000/mm3
Indication or use of (novel) oral anticoagulant therapy
Cardiogenic shock
Chronic total occlusion, left main disease
Inability or contra-indication for MRI
Inability to be followed on-site
Limited life expectancy
DES drug-eluting stent, MRI magnetic resonance imaging, PCI percutaneous coronary intervention, STEMI ST-elevation myocardial infarction
Allocation
Follow-Up
Enrolment Assessment for eligibility
Exclusion
Not meeting inclusion criteria
Declined to participate
Other reasons
At 1 month: IMR, RHI, biomarkers, CMR, OCT
At 1 year: RHI, biomarkers
Randomization 1:1 
Baseline IMR, biomarkers, RHI (n=110)
STEMI patients
Not assessed for study eligibility
Prasugrel (n=55)Ticagrelor (n=55)
Analysis
•
•
•
Fig. 1 Flow chart of the
REDUCE-MVI study. CMR
cardiovascular magnetic
resonance, IMR index of
microcirculatory resistance, OCT
optical coherence tomography,
PCI percutaneous coronary
intervention, RHI reactive
hyperemia index, STEMI ST-
elevation myocardial infarction
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and modified software, the transit time of room-temperature
saline injected in a coronary artery can be determined. After an
intracoronary injection of 200 mcg nitroglycerine to establish
epicardial coronary vasodilatation, the guidewire is calibrated
outside the body, equalized with aortic pressure at the ostium
of the guide catheter, and then advanced into the distal third of
the artery and distal to the stent in the infarct-related artery.
The mean transit time at baseline is obtained by administering
three times 3 mL of intracoronary saline. Thereafter, hyper-
emia is induced by administering adenosine at 140 mcg/kg per
minute intravenously and measurement of mean transit time is
repeated. Aortic and distal coronary pressures are recorded
simultaneously. The distal coronary pressure divided by the
inverse of the hyperemic mean transit time then provides the
IMR. This calculation will be performed by independent and
blinded analysts in a core laboratory.
Optical Coherence Tomography
Optical coherence tomography (OCT) will be performed at
1 month with a Dragonfly™ OCT catheter (St Jude Medical,
St. Paul, MN, USA) using a motorized pullback device. OCT
pullbacks will be performed at a speed of 20 mm/s in the
infarct-related and non-infarct-related arteries, using in gener-
al a contrast flush rate of 3 mL/s in the right coronary artery
and 4 mL/s in the left coronary artery. The occurrence of
subclinical stent thrombus, stent malposition, and edge dissec-
tions will be assessed. All acquired images are sent to a core
laboratory for blinded evaluation (endothelial aspects of the
infarct- and non-infarct-related artery) using a standardized
protocol.
Peripheral Endothelial Function
The peripheral endothelial function will be measured within
24 h after primary PCI, at 1 month, and 1 year follow-up.
EndoPAT® (Itamar Medical Ltd., Caesarea, Israel) is a val-
idated device indicated for non-invasive endothelial and mi-
crovascular function assessment [20–22]. EndoPAT® will be
used to measure the finger arterial pulsatile volume changes
that indicate changes in vascular tone, by modified plethys-
mographic probes placed on the index finger of each hand
[23]. The measurements will be performed at rest in a conve-
nient, low stimulus environment. Each recording consists of
subsequently 5 min of baseline measurement, 5 min of occlu-
sion time of the brachial artery by a blood pressure cuff, and
5 min post-occlusion measurement (hyperemic period).
Measurements will be performed on the contralateral arm of
the access site of angiography. The access site extremity
is used as a reference to control for concurrent non-
endothelial-dependent systemic changes in vascular tone.
The reactive hyperemia index (RHI) and its natural loga-
rithm are then calculated as the ratio of the magnitude of the
average post-occlusive pulse volume amplitude to the average
a
b
2 
c
Fig. 2 Primary PCI procedure with subsequentmeasurement of the IMR.
a Angiographic demonstration of the presence of a subtotal occlusion of
the right coronary artery (RCA) in its mid portion and b final result after
successful reopening of the RCA with subsequent implantation of two
DES stents; cmeasurement of the IMR. The recording is obtained from a
pressure wire in the mid of the right coronary artery of a patient after
primary PCI. The panel is divided into two windows; the upper window
displays the pressure segments recorded during each saline injection,
separated from each other by white vertical lines (mean proximal
arterial pressure (Pa) = 91 and mean distal arterial pressure (Pd) = 81
result into a fractional flow reserve (FFR) = 0.89). The lower graph
displays saline injections at baseline (blue) and during hyperemia
(yellow). Between the two graphs are mean transit time values at
baseline (preceded by “Bas”), and during hyperemia (preceded by “Hyp”)
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pre-occlusive pulse volume amplitude, corrected for baseline
vascular tone.
Cardiovascular Magnetic Resonance
After 1 month and optionally at baseline (day 2–7), CMR will
be performed with a 1.5 or 3.0 Tesla scanner using a phased
array cardiac receiver coil. All images are ECG-gated and ac-
quired during mild end-expiration breath-holding. Cine long-
and short-axis slices are obtained to examine regional and glob-
al left ventricular function, volumes, and ejection fraction.
Evaluation of myocardial ischemia will be assessed with first-
pass perfusion imaging of a gadolinium-based contrast agent
during the administration of 140 mcg/kg per minute of adeno-
sine intravenously. Finally, late gadolinium-enhanced (LGE)
images are acquired 10 min after perfusion imaging, to identify
the size and extent of myocardial infarction and, in addition, the
presence and extent of MVI. When performed at baseline, T2-
weighted imaging will be acquired in short-axis planes for the
detection of intramyocardial hemorrhage and infarct-related
edema. All CMR analyses will be performed in a core labora-
tory by blinded observers using a standardized protocol.
Blood Collection and Storage
Blood samples for laboratory testing will be drawn at baseline
and at 1 month and 1 year follow-up according to standard
procedures. The testing includes standard biochemistry and
hematology tests (e.g., renal function tests, cardiac bio-
markers, lipid profile, and blood cell counts). Furthermore,
extra blood samples will be collected and stored at −80 °C.
At the end of the study, all samples will be analyzed by the
laboratory at the VU University Medical Center. The plasma
levels of ticagrelor will be examined as well, and P2Y12 inhi-
bition levels will be assessed by VerifyNow testing
(Accumetrics, San Diego, CA, USA). The effect of ticagrelor
on inflammatory markers and cells, such as cell adhesion mol-
ecules and monocytes, will be studied concomitantly. In addi-
tion, the level of biochemical markers for endothelial function,
like asymmetrical dimethylarginine, will be measured, which
allows linking these results to the microvascular function.
Registration of Adverse Events
Adverse events (AEs) are evaluated and registered during in-
dex hospitalization and at 1 month and 1 year follow-up. AEs
occurring in external participating centers will be reported to
the sponsor. A serious adverse event (SAE) is a severe unde-
sirable event in which there was no necessarily causality with
the study. The relationship of SAEs to study treatment or
procedures will be assessed by the investigators and commu-
nicated to AstraZeneca.
As a safety measure, bleeding complications will be mon-
itored during the entire study period, categorized to the most
recent criteria (Bleeding Academic Research Consortium,
Thrombolysis in Myocardial Infarction [24], and Global Use
of Strategies to Open Occluded Coronary Arteries [25]) and
analyzed for both treatment groups.
Once a year, the sponsor will submit a safety report to the
accredited medical ethics committee and competent authority.
After 50 % inclusion, an interim analysis will be performed,
with respect to safety endpoints, AEs, and SAEs. An indepen-
dent data safety monitoring board, composed of experienced
cardiologists and a statistician, will be responsible for
reviewing patient safety and study integrity.
Sample Size Calculation
The study is powered using a superiority design with the null
hypothesis that IMR will be significantly improved in the
ticagrelor group in comparison to the prasugrel group. A dif-
ference of IMR means of 7 at 1 month follow-up between the
two treatment groups, with a standard deviation of 12, is ex-
pected [26]. To be able to reject the null hypothesis that the
means of both treatment groups are equal with a power of
80 % (with significance level α=0.05), 47 subjects in each
group are required. Assuming a loss of follow-up of maximal-
ly 15%, it will be necessary to include a total of 110 patients in
the study. After 50 % inclusion (n=55) with complete 30-day
follow-up, an interim analysis will be performed to verify the
assumed standard deviation and, if necessary, we might adjust
the total sample size needed to achieve an adequate power.
Discussion
Optimal therapy of STEMI requires both treatment of the
macrovasculature and the microvasculature. Over the years,
treatment of the macrovasculature has improved notably. Due
to refined stent designs and more biocompatible polymers on
DESs, the prevalence of acute stent thrombosis and restenosis
has been reduced significantly. However, inadequate myocar-
dial perfusion after restoration of the epicardial blood flow by
primary PCI is present in a large proportion of STEMI pa-
tients. Nearly 50 % of the final myocardial infarct size is due
to myocardial reperfusion injury, and thus, a logical target for
reducing myocardial infarct size, thereby maximizing the ben-
efits of reperfusion [27].
The cornerstone of treatment of patients after STEMI is
antithrombotic therapy with a P2Y12-receptor antagonist and
aspirin. According to current ESC and ACCF/AHA guide-
lines, both ticagrelor and prasugrel have a class 1B
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recommendation for use after STEMI [10, 11]. Both of these
drugs have advantages over clopidogrel as they achieve a
more rapid, consistent, and stronger platelet inhibition than
clopidogrel with improved outcomes [28, 29]. With regard
to the efficacy in inhibiting platelet function, ticagrelor and
prasugrel have comparable effects [12]. Currently, the ISAR-
REACT 5 study is enrolling patients to compare ticagrelor and
prasugrel for clinical outcome [13].
It has been shown that ticagrelor, besides its anti-
platelet effects, also has the potency of increasing the
plasma concentration of endogenous adenosine in pa-
tients with acute coronary syndromes. Adenosine is pro-
duced particularly after tissue damage by hypoxia, and
ticagrelor has the ability to inhibit intracellular uptake
through the adenosine equilibrative nucleoside transport-
er 1 (ENT1). Prasugrel and clopidogrel, two other
P2Y12-receptor antagonists, do not mediate such conser-
vation of the plasma adenosine concentration [15, 16].
This indicates that ticagrelor might be a superior drug
for treating STEMI.
There is evidence that elevations of adenosine reduce the
inflammatory response in the different phases after
revascularized myocardial infarction, by interfering with the
production of inflammatory mediators and oxygen species
and neutrophil trafficking [8, 9].
In the acute phase of myocardial infarction, myocardial
damage is enhanced by the formation of microthrombi as a
result of a hypercoagulable state and by inflammatory cell
clogging of the intramyocardial microvasculature. In the early
phase (hours to days), infiltrating cells further amplify dam-
age, as an influx of blood-borne inflammatory cells leads to
production of inflammatory mediators and tissue-destructive
agents such as metalloproteinases [30]. In the late phase of
myocardial infarction (days tomonths), which is characterized
by irreversible damage of the microcirculation, adenosine
might also have beneficial effects, as it stimulates at elevated
levels angiogenesis by the induction of endothelial progenitor
cell migration [31]. Only effective angiogenesis and
arteriogenesis will be able to restore microvascular and
macrovascular tissue perfusion to prevent increased scarring.
Furthermore, adenosine may have a stimulatory effect on en-
dothelial healing, which may be particularly favorable in pa-
tients who underwent successful primary PCI for STEMI.
In these ways, adenosine might reduce ischemia and reper-
fusion injury, preserving microvascular function. This might
be most important for patients with STEMI, as coronary MVI
and dysfunction appear to be most pronounced in this patient
group, compared to patients with non-ST-elevation acute cor-
onary syndrome [32].
In the REDUCE-MVI study, we aim to investigate the po-
tential adenosine-mediated effects of ticagrelor with several
outcome parameters, especially IMR, to determine the effect
on coronary microvascular function.
In the coming years, more insight into the biochemical
mechanisms involved in STEMI may be expected, which
may hopefully lead to the development of more specific drugs
for microvascular preservation. Along this line, the REDUCE-
MVI study is focused in more detail on current therapeutic
options to retain microvascular integrity and function in pa-
tients with STEMI.
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